Key Highlights:
- uniQure (QURE, Financial) revenue and earnings per share fell short of analyst expectations.
- The company's projected revenue growth outpaces the industry average significantly.
- Analyst price targets suggest substantial potential upside from current levels.
uniQure's Financial Performance: A Deep Dive
In the latest financial report, uniQure (NASDAQ: QURE) presented results that did not meet market expectations. Revenue undershot analyst predictions by 31%, while earnings per share lagged behind by 25%. Despite these setbacks, uniQure maintains an optimistic outlook, with projections of a 51% annual revenue growth over the coming three years—more than double the 20% average growth anticipated for the U.S. Biotech industry.
Analyst Insights and Forecasts
According to a consensus of 10 financial analysts, the average price target for uniQure NV (QURE, Financial) is set at $36.70. This target spans a high of $70.00 and a low of $13.00, with the average suggesting a remarkable potential upside of 290.84% from its current trading price of $9.39. For a comprehensive analysis, investors can explore the uniQure NV (QURE) Forecast page.
In assessing brokerage recommendations, 14 firms have provided their insights, resulting in an average rating of 1.8 for uniQure NV (QURE, Financial). This rating falls in the "Outperform" category, based on a scale ranging from 1 (Strong Buy) to 5 (Sell).
Understanding the GF Value of uniQure
On the valuation front, the GF Value metric—GuruFocus' proprietary evaluation of a stock's fair trading value—projects uniQure NV's (QURE, Financial) one-year fair value at $13.56. This indicates an upside potential of 44.41% from its current price of $9.39. The GF Value is calculated through an analysis of historical trading multiples, past growth rates, and future performance projections. For further details, visit the uniQure NV (QURE) Summary page.
